If you are interested in understanding what does cause cancer, watch the first 15 minutes of this PODCAST 12: “Telomerase Doesn’t Cause Cancer”. I believe that telomerase is a retained feature of stemness and that cancer arises usually in stem cells, not telomerase-inactive differentiated cells.
For those wanting a more in-depth understanding of how TA-65 might work, I refer to you an email conversation I had with a patient, who was concerned that a blog referenced a Blasco paper demonstrating a 50% increase in liver cancer in mice after taking TA-65.
This is the conclusion of our interview with Telomere expert, Dr. Sandy Chang, MD, PhD from Yale University. He was interviewed by Dr. Ed Park at the American Academy of Anti-Aging Conference in 2014.
In this segment, Dr. Chang discusses the science linking shortened telomeres to cancer formation with an emphasis on his area of expertise, the SHELTERIN complex that protects the telomere itself.
I would like to try to post at least once a day. We shall see how long this New Years’ resolution lasts…
The inadequate lengthening of telomeres by telomerase allows for mutations to occur. But after carcinogenesis has occurred, the ongoing action of telomerase in those immortal cells allows for lengthening, thereby obscuring the relationship between median telomere length and cancer risk.
Doctors are seldom allowed and even less frequently motivated to deviate from standard of care, which frowns upon removing the dandelion (the primary cancer of origin) after the seeds have spread (the distant metastases).
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
